Calidi Biotherapeutics (CLDI) Preferred Stock Liabilities (2021 - 2023)

Calidi Biotherapeutics has reported Preferred Stock Liabilities for 3 years, with the latest figure at $43.2 million in Q2 2023.

• For the quarter ending Q2 2023, Preferred Stock Liabilities fell 81.23% year-over-year to $43.2 million; the trailing twelve-month figure through Jun 2023 stood at $43.2 million (down 81.23% YoY), and the FY2022 full-year result was $9.6 million, down 95.83% from the prior year.
• Preferred Stock Liabilities for Q2 2023 stood at $43.2 million, up from $42.9 million in the prior quarter.
• The five-year high for Preferred Stock Liabilities was $230.2 million in Q2 2022, with the low at $9.6 million in Q4 2022.
• Average Preferred Stock Liabilities over 3 years is $118.2 million, with a median of $43.2 million recorded in 2023.
• Year-over-year, Preferred Stock Liabilities tumbled 95.83% in 2022 and sank 81.23% in 2023.
• Tracing CLDI's Preferred Stock Liabilities over 3 years: stood at $230.0 million in 2021, then plunged by 95.83% to $9.6 million in 2022, then jumped by 350.1% to $43.2 million in 2023.
• The last three Preferred Stock Liabilities figures came in at $43.2 million (Q2 2023), $42.9 million (Q1 2023), and $9.6 million (Q4 2022), per Business Quant data.

Peer Comparison